Norwegian Multiple Sclerosis Competence Centre - MS

The Norwegian Multiple Sclerosis Competence Centre and the Norwegian MS Registry & Biobank are nationwide services for patients, relatives, health personnel and others who are interested in information on MS. We are not engaged in treatment of patients, but are mainly occupied with research, education and information. The Norwegian MS Registry & Biobank are continuously updated on the incidence and prevalence of MS, and we provide data on epidemiology and spinal fluid for research purposes and epidemiological data for planning of health care and social policy.

The Norwegian Multiple Sclerosis Competence Centre was established in 1996 with financial funding from the Norwegian government.

The Norwegian Multiple Sclerosis Competence Centre is part of the department of Neurology, Haukeland University Hospital. Promotion of research, supervision and counselling of health care professionals and patients are the main responsibilities of the centre.

Our services

We do not have responsibility for treatment of patients. However, nurses and doctors have contact with patients and are engaged in medical treatment at the outpatient clinic at the Department of Neurology, as part of clinical trials and to get the sufficient clinical experience.

In addition, our doctors have responsibility for treatment of MS with mitoxantrone and natalizumab. We also cooperate with The Norwegian MS Society to run a web based Q&A service and a phone service for patients and their relatives.

The most recent update on clinical guidelines is done in collaboration with The Norwegian MS Society, The Norwegian Neurological Association and the Norwegian Directorate of Health.

The Kristian Gerhard Jebsen centre for medical research

Thanks to a generous donation from the K.G. Jebsen foundation and support from the University of Bergen, The K.G. Jebsen centre for MS Research was established in 2011 at The Norwegian Multiple Sclerosis Competence Centre and the Department of Clinical Medicine, University of Bergen.

The aim is to identify biomarkers which can improve diagnostics of MS and define the pathogenesis of the disease, and then a possible explanation of the cause of MS.

The research are focused mainly on epidemiology, immunogenetics, clinical trials and medical treatment.